MDS/MPN with ringed sideroblasts and thrombocytosis, and secondary or concurrent mastocytosis: case report and literature review

被引:0
作者
Younes I.E. [1 ,2 ]
Saeed D.M. [1 ,2 ]
Majeed N. [1 ,2 ]
Hakimian D. [2 ]
Boumendjel R. [2 ]
机构
[1] Department of Pathology, University of Illinois at Chicago, Chicago, IL
[2] Advocate Lutheran General Hospital, Park Ridge, IL
关键词
Mastocytosis; MDS/MPN; Thrombocytosis;
D O I
10.1007/s00580-020-03149-1
中图分类号
学科分类号
摘要
Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN with RS-T), which exhibits both an increased number of marrow ring sideroblasts and thrombocytosis, is a rare disorder classified as one of the newly established forms of MDS/MPN in the WHO 2016 classification. Systemic mastocytosis (SM) is a heterogeneous group of neoplasms characterized by growth and accumulation of both cytologically and immunophenotypically abnormal mast cells in one or more body organ systems. SM can occur as a separate neoplasm but commonly is associated with other clonally related myeloid neoplasms. Herein, we present a 78-year-old female with a clinical history of fatigue, dyspnea, and a compression fracture of L5. Her peripheral blood, bone marrow aspirate, and biopsy laboratory workup show features of myelodysplasia with ring sideroblasts, thrombocytosis, and clusters of mast cells in the bone marrow biopsy. Pathogenic c-KIT, MPL, and SF3B1 genes are identified by the molecular study. We present this case to point out a rare combination of systemic mastocytosis and MDS/MPN with ring sideroblasts and thrombocytosis. It is not known if the best treatment should be focused on the systemic mastocytosis or the accompanying MDS/MPN. © 2020, Springer-Verlag London Ltd., part of Springer Nature.
引用
收藏
页码:1087 / 1090
页数:3
相关论文
共 13 条
  • [1] Bernd H.-W., Sotlar K., Lorenzen J., Osieka R., Fabry U., Valent P., Horny H.P., Acute myeloid leukaemia (AML) with t(8
  • [2] 21) associated with "occult" mastocytosis (SM-AHNMD). p
  • [3] Report of an unusual case and review of the literature, J Clin Pathol, 57, pp. 324-328, (2004)
  • [4] Garcia-Montero A.C., Jara-Acevedo M., Teodosio C., Et al., KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients, Blood, 108, 7, pp. 2366-2372, (2006)
  • [5] Horny H.P., Sotlar K., Stellmacher F., Et al., An unusual case of systemic mastocytosis associated with chronic lymphocytic leukemia (SM-CLL), J Clin Pathol, 59, 3, pp. 264-268, (2006)
  • [6] Horny H.P., Sotlar K., Sperr W.R., Valent P., Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge, J Clin Pathol, 57, 6, pp. 604-608, (2004)
  • [7] Jaffe E.S., World Health Organization Classification of Tumors, (2001)
  • [8] Lim K.H., Tefferi A., Lasho T.L., Finke C., Patnaik M., Butterfield J.H., McClure R.F., Li C.Y., Pardanani A., Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors, Blood, 113, 23, pp. 5727-5736, (2009)
  • [9] Metcalfe D.D., Classification and diagnosis of mastocytosis: Current status, J Invest Dermatol, 96, 3, pp. 2S-4S, (1991)
  • [10] Nagata H., Worobec A.S., Oh C.K., Chowdhury B.A., Tannenbaum S., Suzuki Y., Metcalfe D.D., Identification of a point mutation in the catalytic domain of the protooncogene c-KIT in the peripheral blood mononuclear cells in patients who have mastocytosis with an associated hematological disorder, Proc Natl Acad Sci U S A, 92, 23, pp. 10560-10564, (1995)